Gastrointestinal Disorders Therapeutics Market to 2018 - NovelAgents Targeting Irritable Bowel Syndrome (IBS), ChronicCons...
Scope- Data and analysis for the gastrointestinal disorders therapeutics markets in the leadinggeographies: the US; the to...
3.1.1 Branded and Generic Global Market Share 183.1.2 Annual Cost of Treatment 193.1.3 Treatment Usage Patterns 203.2 Driv...
5.2 Drivers and Restraints for the Irritable Bowel Syndrome Therapeutics Market 555.2.1 Drivers for the Irritable Bowel Sy...
5.9.6 Annual Cost of Treatment 945.9.7 Treatment Usage Patterns 955.10 Drivers and Restraints for the Gastroesophageal Ref...
6.10.10 Asimadoline 1286.10.11 Traficet-EN (GSK-1605786) 1296.10.12 Cobiprostone 1307 Global Gastrointestinal Disorders Th...
9.7 Pipeline Analysis 1709.8 Competitive Landscape 1709.9 Strategic Consolidations 1709.10 Contact Us 1709.11 Disclaimer 1...
Treatment Usage Patterns (Million), 2004–2011 33Table 20: Gastrointestinal Disorders Therapeutics Market, Top Five Countri...
2011–2018 60Table 45: Constipation Therapeutics Market, Global, Annual Cost of Treatment ($), 2004–2011 62Table 46: Consti...
Table 69: Gastroesophageal Reflux Disease Therapeutics Market, Global, Annual Cost ofTreatment ($), 2004–2011 94Table 70: ...
Table 91: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Year,2010–Mid-2012 154Table 92: Gastr...
Irritable Bowel Syndrome 47Figure 18: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue ($m), 2004–2018 48Figu...
2004–2018 82Figure 43: Ulcerative Colitis Therapeutics Market, Global, Treatment Usage Patterns (‘000),2004–2018 83Figure ...
Phase, (%), 2012 114Figure 66: Gastrointestinal Disorders Therapeutics Market, Global, GERD Pipeline by Phase, (%),2012 11...
Upcoming SlideShare
Loading in …5
×

Gastrointestinal Disorders Therapeutics Market to 2018 - Novel Agents Targeting Irritable Bowel Syndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate the Market

240 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
240
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Gastrointestinal Disorders Therapeutics Market to 2018 - Novel Agents Targeting Irritable Bowel Syndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate the Market

  1. 1. Gastrointestinal Disorders Therapeutics Market to 2018 - NovelAgents Targeting Irritable Bowel Syndrome (IBS), ChronicConstipation (CC) and Ulcerative Colitis (UC) to Reinvigoratethe MarketReport Details:Published:November 2012No. of Pages: 171Price: Single User License – US$3500Gastrointestinal Disorders Therapeutics Market to 2018 - Novel Agents Targeting Irritable BowelSyndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate the MarketSummaryGBI Research, the leading business intelligence provider, has released its latest research,“Gastrointestinal Disorders Therapeutics Market to 2018 - Novel Agents Targeting Irritable BowelSyndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate theMarket”, which provides insights into the gastrointestinal disorders therapeutics market until 2018.The report is built using data and information sourced from proprietary databases, primary andsecondary research and in-house analysis by GBI Research’s team of industry experts. It providesin-depth analysis of the major diseases, comprising IBS, constipation, Crohn’s disease, UC,Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD). The report also givesthe size of the generic share in the global gastrointestinal disorders therapeutics market and inthose of the US, the top five countries of Europe, and Japan, as well as treatment usage patternsand geographical distribution. Additionally, it includes insights into the R&D product pipeline andexplores the competitive landscape, looking at major players and including analysis of M&A,licensing agreements and co-development deals that have taken place in the past two years.GBI Research’s analysis shows that the gastrointestinal disorders therapeutics market is set towitness high generic competition in the forecast period, as major drugs used in the treatment ofthe aforementioned disorders are set to expire, resulting in declining revenues and allowinggenerics to enter the market. Nevertheless, the market will witness steady growth due to theanticipated entry of innovative new drugs in the near future. Furthermore, strong R&D in IBS,constipation, Crohn’s disease and UC remains a key market driver.
  2. 2. Scope- Data and analysis for the gastrointestinal disorders therapeutics markets in the leadinggeographies: the US; the top five countries of Europe, comprising the UK, Germany, France, Italyand Spain; Japan; and an overview of India, China and Australia- Annualized market data for the gastrointestinal disorders therapeutics market from 2004 to 2010and forecast to 2018- Market data for the geographical and therapeutic landscapes, including size, share, annual costof therapy, sales volume and treatment usage patterns for the diseased population, diagnosispopulation and prescription population- Generic share in the global market and for each indication- Key drivers and restraints that have had a significant impact on the market- The competitive landscape of the global market, looking at key companies such as AstraZeneca,Takeda, Johnson & Johnson , Eisai, Abbott, Shire and Salix- Key M&A activity and licensing agreements that took place between 2010 and 2012Reasons to buy- Align product portfolios to the markets with high growth potential- Build effective strategies to launch pipeline products by identifying potential geographies- Exploit in-licensing and out-licensing opportunities by identifying products that might fill portfoliogaps- Develop key strategic initiatives by studying top competitors’ key strategies- Device a more tailored country strategy by understanding the key drivers, barriers and marketpotential for each indication- Develop market-entry and market-expansion strategies by identifying the markets poised forstrong growth- Reinforce R&D pipelines by identifying new target mechanisms producing safer and moreefficacious FIC moleculesGet your copy of this report @http://www.reportsnreports.com/reports/202050-gastrointestinal-disorders-therapeutics-market-to-2018-novel-agents-targeting-irritable-bowel-syndrome-ibs-chronic-constipation-cc-and-ulcerative-colitis-uc-to-reinvigorate-the-market.htmlMajor points covered in Table of Contents of this report include1 Table of Contents1 Table of Contents 51.1 List of Tables 91.2 List of Figures 122 Gastrointestinal Disorders Therapeutics Market - Introduction 152.1 Overview 153 Global Gastrointestinal Disorders Therapeutics Market - Market Characterization 163.1 Market Forecasts 16
  3. 3. 3.1.1 Branded and Generic Global Market Share 183.1.2 Annual Cost of Treatment 193.1.3 Treatment Usage Patterns 203.2 Drivers and Restraints for the Global Gastrointestinal Disorders Therapeutics Market 223.2.1 Market Drivers 223.2.2 Market Restraints 234 Gastrointestinal Disorders Therapeutics Market - Geographical Landscape 244.1 Revenue Analysis by Geography 244.2 The US 244.2.1 Revenue 244.2.2 Annual Cost of Treatment 264.2.3 Treatment Usage Patterns 274.3 Top Five Countries of Europe 294.3.1 Revenue 294.3.2 Revenue by Country 304.3.3 Annual Cost of Treatment 324.3.4 Treatment Usage Patterns 334.4 Japan 354.4.1 Revenue 354.4.2 Annual Cost of Treatment 374.4.3 Treatment Usage Patterns 384.5 Gastrointestinal Disorders Therapeutics Market India-Overview 404.5.1 Epidemiology 404.5.2 Clinical Trials 414.5.3 Drivers and Restraints 414.6 Gastrointestinal Disorders Therapeutics Market Australia-Overview 424.6.1 Epidemiology 424.6.2 Clinical Trials 434.6.3 Drivers and Restraints 434.7 Gastrointestinal Disorders Therapeutics Market China-Overview 444.7.1 Epidemiology 444.7.2 Clinical Trials 454.7.3 Drivers and Restraints 455 Global Gastrointestinal Disorders Therapeutics Market - Therapeutic Landscape 465.1 Global Irritable Bowel Syndrome Therapeutics Market Forecasts 465.1.1 Introduction 465.1.2 Treatment Flow Algorithm 475.1.3 Revenue 485.1.4 Revenue by Country 495.1.5 Branded vs. Generic Market Share 515.1.6 Annual Cost of Treatment 525.1.7 Treatment Usage Patterns 53
  4. 4. 5.2 Drivers and Restraints for the Irritable Bowel Syndrome Therapeutics Market 555.2.1 Drivers for the Irritable Bowel Syndrome Therapeutics Market 555.2.2 Restraints for the Irritable Bowel Syndrome Therapeutics Market 555.3 Global Constipation Therapeutics Market Forecasts 565.3.1 Introduction 565.3.2 Treatment Flow Algorithm 575.3.3 Revenue 585.3.4 Revenue Analysis by Country 595.3.5 Branded vs. Generic Market Share 615.3.6 Annual Cost of Treatment 625.3.7 Treatment Usage Patterns 635.4 Drivers and Restraints for the Constipation Therapeutics Market 655.4.1 Drivers for Constipation Therapeutics Market 655.4.2 Restraints for Constipation Therapeutics Market 655.5 Global Crohn’s Disease Therapeutics Market Forecasts 665.5.1 Introduction 665.5.2 Treatment Flow Algorithm 675.5.3 Revenue 685.5.4 Revenue by Country 695.5.5 Branded vs. Generic Market Share 715.5.6 Annual Cost of Treatment 725.5.7 Treatment Usage Patterns 735.6 Drivers and Restraints for the Crohn’s Disease Therapeutics Market 755.6.1 Drivers for the Crohn’s Disease Therapeutics Market 755.6.2 Restraints for the Crohn’s Disease Therapeutics Market 755.7 Global Ulcerative Colitis Therapeutics Market Forecasts 765.7.1 Introduction 765.7.2 Treatment Flow Algorithm 775.7.3 Revenue 785.7.4 Revenue by Country 795.7.5 Branded vs. Generic Market Share 815.7.6 Annual Cost of Treatment 825.7.7 Treatment Usage Patterns 835.8 Drivers and Restraints for the Ulcerative Colitis Therapeutics Market 855.8.1 Drivers for the Ulcerative Colitis Therapeutics Market 855.8.2 Restraints for the Ulcerative Colitis Therapeutics Market 855.9 Global Gastroesophageal Reflux Disease Therapeutics Market Forecasts 865.9.1 Introduction 865.9.2 Treatment Flow Algorithm 875.9.3 Revenue 895.9.4 Revenue by Country 915.9.5 Branded vs. Generic Market Share 93
  5. 5. 5.9.6 Annual Cost of Treatment 945.9.7 Treatment Usage Patterns 955.10 Drivers and Restraints for the Gastroesophageal Reflux Disease Therapeutics Market 975.10.1 Drivers for the Gastroesophageal Reflux Disease Therapeutics Market 975.10.2 Restraints for the Gastroesophageal Reflux Disease Therapeutics Market 975.11 Global Peptic Ulcer Disease Therapeutics Market Forecasts 985.11.1 Introduction 985.11.2 Treatment Flow Algorithm 995.11.3 Revenue 1005.11.4 Revenue Analysis by Country 1025.11.5 Generic vs. Branded Market Share 1045.11.6 Annual Cost of Treatment 1055.11.7 Treatment Usage Patterns 1065.12 Drivers and Restraints for the Peptic Ulcer Disease Therapeutics Market 1085.12.1 Drivers for Peptic Ulcer Disease Therapeutics Market 1085.12.2 Restraints for Peptic Ulcer Disease Therapeutics Market 1086 Global Gastrointestinal Disorders Therapeutics Market - Pipeline Analysis 1096.1 Summary 1096.2 Research and Development Pipeline by Phase 1096.3 Research and Development Pipeline by Indication 1106.4 Irritable Bowel Syndrome: Research and Development Pipeline 1116.4.1 Pipeline by Phase 1116.5 Constipation: Research and Development Pipeline 1126.5.1 Research and Development Pipeline by Phase 1126.6 Crohn’s Disease: Research and Development Pipeline 1136.6.1 Research and Development Pipeline by Phase 1136.7 Ulcerative Colitis: Research and Development Pipeline 1146.7.1 Research and Development Pipeline by Phase 1146.8 Gastroesophageal Reflux Disease: Research and Development Pipeline 1156.8.1 Research and Development Pipeline by Phase 1156.9 Peptic Ulcer Disease: Research and Development Pipeline 1166.9.1 Research and Development Pipeline by Phase 1166.10 Promising Pipeline Molecules 1176.10.1 Linzess (linaclotide) 1186.10.2 Xifaxan (rifaximin) 1206.10.3 Relistor (methylnaltrexone) 1216.10.4 Humira (adalimumab) 1236.10.5 Uceris (budesonide) 1236.10.6 Plecanatide 1246.10.7 Vedolizumab (MLN0002) 1256.10.8 Naloxegol (NKTR-118) 1266.10.9 Simponi (golimumab) 127
  6. 6. 6.10.10 Asimadoline 1286.10.11 Traficet-EN (GSK-1605786) 1296.10.12 Cobiprostone 1307 Global Gastrointestinal Disorders Therapeutics Market - Competitive Landscape 1317.1 Market Share Analysis 1317.2 Profiles of Major Companies 1327.2.1 AstraZeneca 1327.2.2 Takeda Pharmaceutical Company 1337.2.3 Johnson & Johnson 1357.2.4 Eisai Co., Ltd. 1367.2.5 Abbott Laboratories 1377.2.6 Shire 1387.2.7 Salix Pharmaceuticals 1398 Global Gastrointestinal Disorders Therapeutics Market - Strategic Consolidations 1428.1 Overview 1428.2 Mergers and Acquisitions 1438.2.1 Major Mergers and Acquisitions Deals 1438.2.2 Segmentation by Geography 1468.2.3 Segmentation by Deal Value 1478.2.4 Segmentation by Year 1488.3 Licensing Deals 1498.3.1 Major Licensing Deals 1498.3.2 Segmentation by Geography 1528.3.3 Segmentation by Deal Value 1538.3.4 Segmentation by Year 1548.4 Co-development/Co-marketing Deals 1558.4.1 Major Co-development/Co-marketing Deals 1558.4.2 Segmentation by Geography 1588.4.3 Segmentation by Deal Value 1598.4.4 Segmentation by Year 1609 Gastrointestinal Disorders Therapeutics Market - Appendix 1619.1 Abbreviations 1619.2 Market Definitions 1629.3 Bibliography 1629.4 Research Methodology 1669.4.1 Secondary Research 1669.4.2 Primary Research 1669.4.3 Expert Panel Validation 1679.4.4 Section-wise Research Methodology 1679.5 Therapeutic Landscape 1679.5.2 Market Size by Geography 1699.6 Geographical Landscape 170
  7. 7. 9.7 Pipeline Analysis 1709.8 Competitive Landscape 1709.9 Strategic Consolidations 1709.10 Contact Us 1709.11 Disclaimer 1711.1 List of TablesTable 1: Gastrointestinal Disorders Therapeutics Market, Global, Revenue ($bn), 2004–2011 16Table 2: Gastrointestinal Disorders Therapeutics Market, Global, Revenue Forecasts ($bn),2011–2018 16Table 3: Gastrointestinal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($),2004–2011 19Table 4: Gastrointestinal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($),2011–2018 19Table 5: Gastrointestinal Disorders Therapeutics Market, Global, Treatment Usage Pattern(Million), 2004–2011 20Table 6: Gastrointestinal Disorders Therapeutics Market, Global, Treatment Usage Pattern(Million), 2011–2018 21Table 7: Gastrointestinal Disorders Therapeutics Market, The US, Revenue ($bn), 2004–2011 24Table 8: Gastrointestinal Disorders Therapeutics Market, The US, Revenue Forecasts ($bn),2011–2018 24Table 9: Gastrointestinal Disorders Therapeutics Market, The US, Annual Cost of Treatment ($),2004–2011 26Table 10: Gastrointestinal Disorders Therapeutics Market, The US, Annual Cost of Treatment ($),2011–2018 26Table 11: Gastrointestinal Disorders Therapeutics Market, The US, Treatment Usage Patterns(‘000), 2004–2011 27Table 12: Gastrointestinal Disorders Therapeutics Market, The US, Treatment Usage Patterns(‘000), 2011–2018 28Table 13: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue($bn), 2004–2011 29Table 14: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, RevenueForecast, ($bn), 2011–2018 29Table 15: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Revenueby Country ($bn), 2004–2011 30Table 16: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, RevenueForecasts by Country ($bn), 2011–2018 31Table 17: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, AnnualCost of Treatment ($), 2004–2011 32Table 18: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, AnnualCost of Treatment ($), 2011–2018 32Table 19: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe,
  8. 8. Treatment Usage Patterns (Million), 2004–2011 33Table 20: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe,Treatment Usage Patterns (Million), 2011–2018 34Table 21: Gastrointestinal Disorders Therapeutics Market, Japan, Revenue ($bn), 2004–2011 35Table 22: Gastrointestinal Disorders Therapeutics Market, Japan, Revenue Forecasts, ($bn),2011–2018 35Table 23: Gastrointestinal Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($),2004–2011 37Table 24: Gastrointestinal Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($),2011–2018 37Table 25: Gastrointestinal Disorders Therapeutics Market, Japan, Treatment Usage Patterns(‘000), 2004–2011 38Table 26: Gastrointestinal Disorders Therapeutics Market, Japan, Treatment Usage Patterns(‘000), 2011–2018 39Table 27: Gastrointestinal Disorders Therapeutics Market, Diseased Population (‘000), India, 201140Table 28: Gastrointestinal Disorders Therapeutics Market, Pipeline Molecules, India, 2012 41Table 29: Gastrointestinal Disorders Therapeutics Market, Diseased Population (‘000), Australia,2011 42Table 30: Gastrointestinal Disorders Therapeutics Market, Pipeline Molecules, Australia, 2012 43Table 31: Gastrointestinal Disorders Therapeutics Market, Diseased Population (‘000), China,2011 44Table 32: Gastrointestinal Disorders Therapeutics Market, Pipeline Molecules, China, 2012 45Table 33: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue ($m), 2004–2011 48Table 34: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue Forecasts ($m),2011–2018 48Table 35: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue by Country ($m),2004–2011 49Table 36: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue Forecast by Country($m), 2011–2018 50Table 37: Irritable Bowel Syndrome Therapeutics Market, Global, Annual Cost of Treatment ($),2004–2011 52Table 38: Irritable Bowel Syndrome Therapeutics Market, Global, Annual Cost of Treatment ($),2011–2018 52Table 39: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Usage Patterns(‘000), 2004–2011 53Table 40: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Usage Patterns(‘000), 2011–2018 54Table 41: Constipation Therapeutics Market, Global, Revenue ($m), 2004–2011 58Table 42: Constipation Therapeutics Market, Global, Revenue Forecasts ($m), 2011–2018 58Table 43: Constipation Therapeutics Market, Global, Revenue by Country ($m), 2004–2011 59Table 44: Constipation Therapeutics Market, Global, Revenue Forecasts by Country ($m),
  9. 9. 2011–2018 60Table 45: Constipation Therapeutics Market, Global, Annual Cost of Treatment ($), 2004–2011 62Table 46: Constipation Therapeutics Market, Global, Annual Cost of Treatment ($), 2011–2018 62Table 47: Constipation Therapeutics Market, Global, Treatment Usage Patterns (‘000), 2004–201163Table 48: Constipation Therapeutics Market, Global, Treatment Usage Patterns (‘000), 2011–201864Table 49: Crohn’s Disease Therapeutics Market, Global, Revenue ($m), 2004–2011 68Table 50: Crohn’s Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2011–2018 68Table 51: Crohn’s Disease Therapeutics Market, Global, Revenue by Country ($m), 2004–2011 69Table 52: Crohn’s Disease Therapeutics Market, Global, Revenue Forecasts by Country ($m),2011–2018 70Table 53: Crohn’s Disease Therapeutics Market, Global, Annual Cost of Treatment ($),2004–2011 72Table 54: Crohn’s Disease Therapeutics Market, Global, Annual Cost of Treatment ($),2011–2018 72Table 55: Crohn’s Disease Therapeutics Market, Global, Treatment Usage Patterns, 2004–201173Table 56: Crohn’s Disease Therapeutics Market, Global, Treatment Usage Patterns, 2011–201874Table 57: Ulcerative Colitis Therapeutics Market, Global, Revenue ($m), 2004–2011 78Table 58: Ulcerative Colitis Therapeutics Market, Global, Revenue Forecasts ($m), 2011–2018 78Table 59: Ulcerative Colitis Therapeutics Market, Global, Revenue by Country ($m), 2004–201179Table 60: Ulcerative Colitis Therapeutics Market, Global, Revenue Forecast by Country ($m),2011–2018 80Table 61: Ulcerative Colitis Therapeutics Market, Global, Annual Cost of Treatment ($),2004–2011 82Table 62: Ulcerative Colitis Therapeutics Market, Global, Annual Cost of Treatment ($),2011–2018 82Table 63: Ulcerative Colitis Therapeutics Market, Global, Treatment Usage Patterns (‘000),2004–2011 83Table 64: Ulcerative Colitis Therapeutics Market, Global, Treatment Usage Patterns (‘000),2011–2018 84Table 65: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue ($m),2004–2011 89Table 66: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue Forecasts($m), 2011–2018 89Table 67: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue by Country($m), 2004–2011 91Table 68: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue Forecasts byCountry ($m), 2011–2018 92
  10. 10. Table 69: Gastroesophageal Reflux Disease Therapeutics Market, Global, Annual Cost ofTreatment ($), 2004–2011 94Table 70: Gastroesophageal Reflux Disease Therapeutics Market, Global, Annual Cost ofTreatment ($), 2011–2018 94Table 71: Gastroesophageal Reflux Disease Therapeutics Market, Global, Treatment UsagePatterns (‘000), 2004–2011 95Table 72: Gastroesophageal Reflux Disease Therapeutics Market, Global, Treatment UsagePatterns (‘000), 2011–2018 96Table 73: Peptic Ulcer Disease Therapeutics Market, Global, Revenue ($m), 2004–2011 100Table 74: Peptic Ulcer Disease Therapeutics Market, Global, Revenue Forecasts ($m),2011–2018 100Table 75: Peptic Ulcer Disease Therapeutics Market, Global, Revenue by Country ($m),2004–2011 102Table 76: Peptic Ulcer Disease Therapeutics Market, Global, Revenue Forecasts by Country ($m),2011–2018 103Table 77: Peptic Ulcer Disease Therapeutics Market, Global, Annual Cost of Treatment ($),2004–2011 105Table 78: Peptic Ulcer Disease Therapeutics Market, Global, Annual Cost of Treatment ($),2011–2018 105Table 79: Peptic Ulcer Disease Therapeutics Market, Global, Treatment Usage Patterns (‘000),2004–2011 106Table 80: Peptic Ulcer Disease Therapeutics Market, Global, Treatment Usage Patterns (‘000),2011–2018 107Table 81: Gastrointestinal Disorders Therapeutics Market, Global, NDA-filed Molecules, 2012 117Table 82: Gastrointestinal Disorders Therapeutics Market, Global, Promising Phase III Molecules,2012 117Table 83: Gastrointestinal Disorders Therapeutics Market, Global, Promising Phase II Molecules,2012 117Table 84: Gastrointestinal Disorders Therapeutics Market, Global, Major M&A Deals, 2010–Mid2012 143Table 85: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Geography,2010–Mid-2012 146Table 86: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Value (%),2010–Mid-2012 147Table 87: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Year, 2010–Mid-2012 148Table 88: Gastrointestinal Disorders Therapeutics Market, Global, Major Licensing Deals,2010–Mid-2012 149Table 89: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Geography,2010–Mid-2012 152Table 90: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Value,2010–Mid 2012 153
  11. 11. Table 91: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Year,2010–Mid-2012 154Table 92: Gastrointestinal Disorders Therapeutics Market, Global, Major Co-development/Co-Marketing Deals, 2010–Mid-2012 155Table 93: Gastrointestinal Disorders Therapeutics Market, Global, Co-development/MarketingDeals by Geography, 2010–Mid-2012 158Table 94: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Value,2010–Mid-2012 159Table 95: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Year,2010–Mid-2012 1601.2 List of FiguresFigure 1: Gastrointestinal Disorders Therapeutics Market, Global, Revenue ($bn), 2004–2018 16Figure 2: Gastrointestinal Disorders Therapeutics Market, Global, Branded and Generic MarketShare (%), 2011 18Figure 3: Gastrointestinal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($),2004–2018 19Figure 4: Gastrointestinal Disorders Therapeutics Market, Global, Treatment Usage Pattern(Million), 2004–2018 20Figure 5: Gastrointestinal Disorders Therapeutics Market, Global, Market Drivers and Restraints22Figure 6: Gastrointestinal Disorders Therapeutics Market, The US, Revenue ($bn), 2004–2018 24Figure 7: Gastrointestinal Disorders Therapeutics Market, The US, Annual Cost of Treatment ($),2004–2018 26Figure 8: Gastrointestinal Disorders Therapeutics Market, The US, Treatment Usage Patterns(‘000), 2004–2018 27Figure 9: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue($bn), 2004–2018 29Figure 10: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe,Revenue by Country ($bn), 2004–2018 30Figure 11: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, AnnualCost of Treatment ($), 2004–2018 32Figure 12: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe,Treatment Usage Patterns (Million), 2004–2018 33Figure 13: Gastrointestinal Disorders Therapeutics Market, Japan, Revenue ($bn), 2004–2018 35Figure 14: Gastrointestinal Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($),2004–2018 37Figure 15: Gastrointestinal Disorders Therapeutics Market, Japan, Treatment Usage Patterns(‘000), 2004–2018 38Figure 16: Irritable Bowel Syndrome Therapeutics Market, Global, Breakdown of Irritable BowelSyndrome Subtypes(%), 2012 46Figure 17: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Flow Algorithm for
  12. 12. Irritable Bowel Syndrome 47Figure 18: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue ($m), 2004–2018 48Figure 19: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue by Country ($m),2004–2018 49Figure 20: Irritable Bowel Syndrome Therapeutics Market, Global, Branded vs. Generic MarketShare (%), 2011 51Figure 21: Irritable Bowel Syndrome Therapeutics Market, Global, Annual Cost of Treatment ($),2004–2018 52Figure 22: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Usage Patterns(‘000), 2004–2018 53Figure 23: Irritable Bowel Syndrome Therapeutics Market, Global, Market Drivers and Restraints55Figure 24: Constipation Therapeutics Market, Global, Treatment Flow Algorithm for Constipation57Figure 25: Constipation Therapeutics Market, Global, Revenue ($m), 2004–2018 58Figure 26: Constipation Therapeutics Market, Global, Revenue by Country ($m), 2004–2018 59Figure 27: Constipation Therapeutics Market, Global, Branded vs. Generic Market Share (%),2011 61Figure 28: Constipation Therapeutics Market, Global, Annual Cost of Treatment ($), 2004–2018 62Figure 29: Constipation Therapeutics Market, Global, Treatment Usage Patterns (‘000),2004–2018 63Figure 30: Constipation Therapeutics Market, Global, Market Drivers and Restraints 65Figure 31: Crohn’s Disease Therapeutics Market, Global, Treatment Flow Algorithm for Crohn’sDisease 67Figure 32: Crohn’s Disease Therapeutics Market, Global, Revenue ($m), 2004–2018 68Figure 33: Crohn’s Disease Therapeutics Market, Global, Revenue by Country ($m), 2004–201869Figure 34: Crohn’s Disease Therapeutics Market, Global, Branded vs. Generic Market Share (%),2011 71Figure 35: Crohn’s Disease Therapeutics Market, Global, Annual Cost of Treatment ($),2004–2018 72Figure 36: Crohn’s Disease Therapeutics Market, Global, Treatment Usage Patterns, 2004–201873Figure 37: Crohn’s Disease Therapeutics Market, Global, Market Drivers and Restraints 75Figure 38: Ulcerative Colitis Therapeutics Market, Global, Treatment Flow Algorithm for UlcerativeColitis 77Figure 39: Ulcerative Colitis Therapeutics Market, Global, Revenue ($m), 2004–2018 78Figure 40: Ulcerative Colitis Therapeutics Market, Global, Revenue by Country ($m), 2004–201879Figure 41: Ulcerative Colitis Therapeutics Market, Global, Branded vs. Generic Market Share (%),2011 81Figure 42: Ulcerative Colitis Therapeutics Market, Global, Annual Cost of Treatment ($),
  13. 13. 2004–2018 82Figure 43: Ulcerative Colitis Therapeutics Market, Global, Treatment Usage Patterns (‘000),2004–2018 83Figure 44: Ulcerative Colitis Therapeutics Market, Global, Market Drivers and Restraints 85Figure 45: Gastroesophageal Reflux Disease Therapeutics Market, Global, Treatment FlowAlgorithm for Self and Primary-care Treatment 87Figure 46: Gastroesophageal Reflux Disease Therapeutics Market, Global, Treatment FlowAlgorithm for Secondary-care Treatment 88Figure 47: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue ($m),2004–2018 89Figure 48: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue by Country($m), 2004–2018 91Figure 49: Gastroesophageal Reflux Disease Therapeutics Market, Global, Branded vs. GenericMarket Share (%), 2011 93Figure 50: Gastroesophageal Reflux Disease Therapeutics Market, Global, Annual Cost ofTreatment ($), 2004–2018 94Figure 51: Gastroesophageal Reflux Disease Therapeutics Market, Global, Treatment UsagePatterns (‘000), 2004–2018 95Figure 52: Gastroesophageal Reflux Disease Therapeutics Market, Market Drivers and Restraints97Figure 53: Peptic Ulcer Disease Therapeutics Market, Global, Treatment Flow Algorithm 99Figure 54: Peptic Ulcer Disease Therapeutics Market, Global, Revenue ($m), 2004–2018 100Figure 55: Peptic Ulcer Disease Therapeutics Market, Global, Revenue by Country ($m),2004–2018 102Figure 56: Peptic Ulcer Disease Therapeutics Market, Global, Generic vs. Branded Market Share(%) 104Figure 57: Peptic Ulcer Disease Therapeutics Market, Global, Annual Cost of Treatment ($),2004–2018 105Figure 58: Peptic Ulcer Disease Therapeutics Market, Global, Treatment Usage Patterns (‘000),2004–2018 106Figure 59: Peptic Ulcer Disease Therapeutics Market, Market Drivers and Restraints 108Figure 60: Gastrointestinal Disorders Therapeutics Market, Global, Pipeline by Phase, (%), 2012109Figure 61: Gastrointestinal Disorders Therapeutics Market, Global, Pipeline by Indication, (%),2012 110Figure 62: Gastrointestinal Disorders Therapeutics Market, Global, IBS Pipeline by Phase, (%),2012 111Figure 63: Gastrointestinal Disorders Therapeutics Market, Global, Constipation Pipeline byPhase, (%), 2012 112Figure 64: Gastrointestinal Disorders Therapeutics Market, Global, Crohn’s Disease Pipeline byPhase, (%), 2012 113Figure 65: Gastrointestinal Disorders Therapeutics Market, Global, Ulcerative Colitis Pipeline by
  14. 14. Phase, (%), 2012 114Figure 66: Gastrointestinal Disorders Therapeutics Market, Global, GERD Pipeline by Phase, (%),2012 115Figure 67: Gastrointestinal Disorders Therapeutics Market, Global, Peptic Ulcer Disease Pipelineby Phase, (%), 2012 116Figure 68: Gastrointestinal Disorders Therapeutics Market, Global, Market Share by Company, %,2011 131Figure 69: Gastrointestinal Disorders Therapeutics Market, AstraZeneca, SWOT Analysis 132Figure 70: Gastrointestinal Disorders Therapeutics Market, Takeda Pharmaceutical Company,SWOT Analysis 134Figure 71: Gastrointestinal Disorders Therapeutics Market, Johnson & Johnson, SWOT Analysis135Figure 72: Gastrointestinal Disorders Therapeutics Market, Eisai Company Limited, SWOTAnalysis 136Figure 73: Gastrointestinal Disorders Therapeutics Market, Abbott Laboratories, SWOT Analysis137Figure 74: Gastrointestinal Disorders Therapeutics Market, Shire, SWOT Analysis 138Figure 75: Gastrointestinal Disorders Therapeutics Market, Salix Pharmaceuticals, SWOTAnalysis 140Figure 76: Gastrointestinal Disorders Therapeutics Market, Deals by Type, 2010–Mid-2012 142Figure 77: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Geography,2010–Mid-2012 146Figure 78: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Value (%),2010–Mid-2012 147Figure 79: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Year,2010–Mid-2012 148Figure 80: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Geography,2010–Mid-2012 152Figure 81: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Value ($m),2010–Mid-2012 153Figure 82: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Year,2010–Mid-2012 154Figure 83: Gastrointestinal Disorders Therapeutics Market, Global, Co-development Deals byGeography, 2010–Mid-2012 158Figure 84: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Value ($m),2010–Mid-2012 159Figure 85: Gastrointestinal Disorders Therapeutics Market, Global, Co-development Deals byYear, 2010–Mid 2012 160Figure 86: GBI Research Market Forecasting Model 169Contact: sales@reportsandreports.com for more information.

×